KALY Confirms Pharmaceutical Cannabis Extract Report On Recent Trials Scheduled For Tomorrow

KALY Confirms Pharmaceutical Cannabis Extract Report On Recent Trials Scheduled For Tomorrow

Dallas, TX -- March 21, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates.  The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. 

KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies.  In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships.

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
[e-mail]
[phone]